Q2 2022 Earnings Forecast for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Issued By SVB Leerink

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHGet Rating) – Equities researchers at SVB Leerink boosted their Q2 2022 earnings estimates for shares of Deciphera Pharmaceuticals in a note issued to investors on Wednesday, May 4th. SVB Leerink analyst A. Berens now anticipates that the company will post earnings per share of ($0.55) for the quarter, up from their previous estimate of ($0.63). SVB Leerink also issued estimates for Deciphera Pharmaceuticals’ Q3 2022 earnings at ($0.49) EPS, Q4 2022 earnings at ($0.46) EPS, FY2022 earnings at ($2.23) EPS, FY2023 earnings at ($2.19) EPS, FY2024 earnings at ($1.79) EPS, FY2025 earnings at ($0.21) EPS and FY2026 earnings at $1.91 EPS.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.03. The company had revenue of $29.22 million during the quarter, compared to analyst estimates of $27.17 million. Deciphera Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 279.96%. The business’s revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.06) EPS.

Separately, Barclays lowered Deciphera Pharmaceuticals from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $11.00 to $6.00 in a research report on Monday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.11.

Shares of DCPH opened at $9.68 on Monday. The firm has a market cap of $566.78 million, a price-to-earnings ratio of -1.98 and a beta of 1.41. The business has a 50 day moving average price of $9.40. Deciphera Pharmaceuticals has a 52 week low of $6.51 and a 52 week high of $11.47.

In other news, major shareholder Brightstar Associates Llc purchased 1,478,978 shares of the stock in a transaction dated Friday, April 29th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $14,789,780.00. Following the transaction, the insider now owns 18,051,348 shares in the company, valued at $180,513,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 3,718 shares of company stock worth $33,648. 4.10% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its holdings in shares of Deciphera Pharmaceuticals by 128.7% during the 2nd quarter. Morgan Stanley now owns 44,132 shares of the company’s stock valued at $1,615,000 after buying an additional 24,834 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Deciphera Pharmaceuticals by 11.5% during the 2nd quarter. Bank of America Corp DE now owns 17,682 shares of the company’s stock valued at $647,000 after buying an additional 1,828 shares during the last quarter. BlackRock Inc. lifted its holdings in Deciphera Pharmaceuticals by 0.4% in the 3rd quarter. BlackRock Inc. now owns 3,694,905 shares of the company’s stock worth $125,554,000 after purchasing an additional 13,692 shares during the last quarter. Barclays PLC lifted its holdings in Deciphera Pharmaceuticals by 109.2% in the 3rd quarter. Barclays PLC now owns 63,579 shares of the company’s stock worth $2,161,000 after purchasing an additional 33,186 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter worth approximately $221,000. Institutional investors and hedge funds own 87.97% of the company’s stock.

Deciphera Pharmaceuticals Company Profile (Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Featured Stories

Earnings History and Estimates for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.